Top

BY Kelly Calagna

Updated results from two MD Anderson clinical trials presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting indicate improved outcomes for cancer patients with specific gene mutations when treated with targeted therapies. Targeted therapies from both the BEACON CRC and the BLC2001 clinical trials resulted in FDA approvals of treatments for subsets of patients with advanced colorectal and bladder cancers....

DNA mutation illustration

BY Scott Merville

Bladder cancer patients with advanced disease have a new option for treatment after the Food and Drug Administration (FDA) this week approved...

BY Scott Merville

Combination immunotherapy is producing response rates ranging from 26 to 38% among patients with metastatic bladder cancer in a clinical trial led by MD Anderson Cancer Center.

“Until the first, recent approval of immune checkpoint therapy, patients with bladder cancer have not had new treatment options for over 30 years. We’re quickly moving from immune checkpoint monotherapy to immune checkpoint combination therapies to improve...

bladder cancer combination immunotherapy treatment clinical trial

BY Laura Sussman

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless...